Dupilumab Significantly Improves Hand Eczema and Quality of Life, Finds Study
USA: Researchers have found in a new study that a 16-week course of dupilumab significantly improved hand eczema symptoms and led to meaningful gains in health-related quality of life (HRQoL). The findings highlight the effectiveness of dupilumab as a treatment option for patients with atopic hand eczema.
The findings, published in the Journal of the American Academy of Dermatology, are based on a post hoc analysis led by Eric L. Simpson from the Department of Dermatology, Oregon Health & Science University, Portland, and colleagues.
Chronic hand eczema can significantly disrupt daily activities, reduce work productivity, increase healthcare use, and impair quality of life. Although dupilumab has been shown to improve the clinical signs and symptoms of atopic hand eczema, its effects on patient-reported quality of life remained unclear.
To investigate this, researchers conducted a post hoc analysis of the randomized, placebo-controlled LIBERTY-AD-HAFT trial involving patients aged 12 years and older with moderate-to-severe atopic hand eczema and no or mild atopic dermatitis outside the hands and feet.
Health-related quality of life was assessed using the validated Quality of Life in Hand Eczema Questionnaire (QoLHEQ), with a reduction of at least 22 points considered clinically meaningful.
Each treatment group included 30 patients. At baseline, nearly 90% reported at least moderate impairment in quality of life, with most having moderate atopic hand eczema and about one-quarter having severe disease.
Key findings from the study include:
- Significantly more patients receiving dupilumab achieved a clinically meaningful improvement in QoLHEQ scores from week 4 through week 16 compared with placebo.
- By week 16, 72.4% of patients treated with dupilumab achieved the minimal important improvement in quality of life versus 37.9% in the placebo group.
- At the end of treatment, 66.6% of dupilumab-treated patients reported no or only slight impairment in quality of life compared with 43.3% of those receiving placebo.
- Dupilumab significantly improved overall QoLHEQ scores and produced greater improvements in the Symptoms, Emotions, and Treatment/Prevention domains, while also showing numerically greater benefits in daily functioning.
- Improvements were reflected across individual questionnaire items, with patients reporting less frequent disruption of everyday activities and emotional well-being.
The researchers noted that even when atopic dermatitis is largely limited to the hands, it can have a profound impact on patients' quality of life despite affecting a relatively small body surface area.
The authors concluded that 16 weeks of dupilumab treatment produced clinically meaningful improvements in health-related quality of life across multiple domains in patients with moderate-to-severe atopic hand eczema. They added that the consistent benefits observed across symptoms, emotional health, and daily functioning further support dupilumab as an effective therapeutic option for this difficult-to-treat condition.
Reference:
Simpson EL, Schuttelaar MA, Molin S, Gonçalo M, Oosterhaven JAF, Gao XH, Uppal S, Delevry D, Korotzer A, Rossi AB. Dupilumab treatment improves health-related quality of life in patients with moderate-to-severe atopic dermatitis primarily affecting the hands (atopic hand eczema): Results from a randomized placebo-controlled trial. J Am Acad Dermatol. 2026 May;94(5):1513-1517. doi: 10.1016/j.jaad.2025.12.079. Epub 2025 Dec 26. PMID: 41456798.
Next Story